The new business combines solutions from four companies and will target customers in pharma and biotech, consumer markets, ...

Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

In this GEN webinar, experts from WuXi AppTec will share essential strategies and methodologies for accelerating pre-clinical ...

For this new study, a team tested the engineered D22 compound against several priority bacterial infections in animals. In ...

The new facility complements existing mammalian-derived product manufacturing at 6,000L and 20,000L scales provided from ...

By understanding more about the cycle of inflammation, it might be possible to find new ways to prevent or treat this in IBD.

Controlling the dissolved oxygen in bioreactors sets the stage for developing new treatments for liver disease.

The NATi mRNA BioFoundry is part of an ongoing effort to strengthen Singapore’s position in nucleic acid therapeutics.

Waters added Wyatt Tehnology’s light scattering instruments to their portfolio last yeaf. According to Pittman, the company ...

Scientists have created a novel technology for developing antibody (M6P) conjugates without enzyme modification in vitro, ...

RevOpsis says it is committed to the rapid discovery and development of novel multispecific therapies utilizing its modular ...